WO2024026707A1 - Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci - Google Patents

Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci Download PDF

Info

Publication number
WO2024026707A1
WO2024026707A1 PCT/CN2022/109857 CN2022109857W WO2024026707A1 WO 2024026707 A1 WO2024026707 A1 WO 2024026707A1 CN 2022109857 W CN2022109857 W CN 2022109857W WO 2024026707 A1 WO2024026707 A1 WO 2024026707A1
Authority
WO
WIPO (PCT)
Prior art keywords
exogenous antigen
tumor
cells
antigen
sortase
Prior art date
Application number
PCT/CN2022/109857
Other languages
English (en)
Inventor
Zhike LU
Lijia MA
Ke NI
Original Assignee
Westlake Genetech. Ltd.
Westlake University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westlake Genetech. Ltd., Westlake University filed Critical Westlake Genetech. Ltd.
Priority to PCT/CN2022/109857 priority Critical patent/WO2024026707A1/fr
Priority to PCT/CN2023/110768 priority patent/WO2024027764A2/fr
Publication of WO2024026707A1 publication Critical patent/WO2024026707A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2207—Sortase A (3.4.22.70)

Abstract

La présente divulgation concerne un système de CAR intelligent, où un antigène exogène est marqué sur des cellules tumorales, les cellules tumorales marquées avec l'antigène exogène peuvent être reconnues par des cellules immunitaires ingéniérisées qui expriment un récepteur chimérique comprenant un domaine de liaison qui se lie à l'antigène exogène, et la tumeur peut être éliminée au moins en partie. La présente divulgation concerne également des procédés de préparation, des procédés de traitement et des utilisations associées au système de CAR intelligent.
PCT/CN2022/109857 2022-08-03 2022-08-03 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci WO2024026707A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2022/109857 WO2024026707A1 (fr) 2022-08-03 2022-08-03 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci
PCT/CN2023/110768 WO2024027764A2 (fr) 2022-08-03 2023-08-02 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/109857 WO2024026707A1 (fr) 2022-08-03 2022-08-03 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
WO2024026707A1 true WO2024026707A1 (fr) 2024-02-08

Family

ID=83280498

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2022/109857 WO2024026707A1 (fr) 2022-08-03 2022-08-03 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci
PCT/CN2023/110768 WO2024027764A2 (fr) 2022-08-03 2023-08-02 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/110768 WO2024027764A2 (fr) 2022-08-03 2023-08-02 Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci

Country Status (1)

Country Link
WO (2) WO2024026707A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020206359A1 (en) * 2019-01-10 2021-07-29 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expansion and uses thereof

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BRADSHAW, W.J. ET AL.: "Molecular features of the sortase enzyme family", FEBS J, vol. 282, 2015, pages 2097 - 2114
CHAMPIAT STSELIKAS LFARHANE SRAOULT TTEXIER MLANOY E ET AL.: "Intratumoral Immunotherapy: From Trial Design to Clinical Practice", CLIN CANCER RES., vol. 27, no. 3, 2021, pages 665 - 79
CHEN, I.DORR, B.M.LIU, D.R.: "A general strategy for the evolution of bond-forming enzymes using yeast display", PROC NATL ACAD SCI USA, vol. 108, 2011, pages 11399 - 11404, XP055299966, DOI: 10.1073/pnas.1101046108
CHEN, L. ET AL.: "Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency", SCI REP, vol. 6, 2016, pages 31899
DAVID T. RODGERS ET AL: "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 4, 26 January 2016 (2016-01-26), pages E459 - E468, XP055260066, ISSN: 0027-8424, DOI: 10.1073/pnas.1524155113 *
GE YCHEN LLIU SZHAO JZHANG HCHEN PR: "Enzyme-Mediated Intercellular Proximity Labeling for Detecting Cell-Cell Interactions", J AM CHEM SOC., vol. 141, no. 5, 2019, pages 1833 - 7, XP055726676, DOI: 10.1021/jacs.8b10286
GE, Y. ET AL.: "Enzyme-Mediated Intercellular Proximity Labeling for Detecting Cell-Cell Interactions", JAM CHEM SOC, vol. 141, 2019, pages 1833 - 1837, XP055726676, DOI: 10.1021/jacs.8b10286
GLASGOW, J.E.SALIT, M.L.COCHRAN, J.R: "In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase Variant", JAM CHEM SOC, vol. 138, 2016, pages 7496 - 7499, XP055576669, DOI: 10.1021/jacs.6b03836
MARABELLE ATSELIKAS LDE BAERE THOUOT R: "Intratumoral immunotherapy: using the tumor as the remedy", ANN ONCOL., vol. 28, 2017, pages xii33 - xii43, XP055724506, DOI: 10.1093/annonc/mdx683
MAROFI FMOTAVALLI RSAFONOV VATHANGAVELU LYUMASHEV AVALEXANDER M ET AL.: "CAR T cells in solid tumors: challenges and opportunities", STEM CELL RES THER., vol. 12, no. 1, 2021, pages 81
MARTINEZ MMOON EK: "CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment", FRONT IMMUNOL, vol. 10, 2019, pages 128, XP055727858, DOI: 10.3389/fimmu.2019.00128
MELERO ICASTANON EALVAREZ MCHAMPIAT SMARABELLE A: "Intratumoural administration and tumour tissue targeting of cancer immunotherapies", NAT REV CLIN ONCOL., vol. 18, no. 9, 2021, pages 558 - 76, XP037541763, DOI: 10.1038/s41571-021-00507-y
PARK KYOUNGSOOK ET AL: "Anchoring foreign substances on live cell surfaces using Sortase A specific binding peptide", CHEMICAL COMMUNICATIONS, vol. 49, no. 83, 1 January 2013 (2013-01-01), UK, pages 9585 - 9587, XP093015205, ISSN: 1359-7345, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2013/cc/c3cc44753g> DOI: 10.1039/c3cc44753g *
PASQUAL GIULIA ET AL: "Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling", NATURE, vol. 553, no. 7689, 1 January 2018 (2018-01-01), London, pages 496 - 500, XP093016044, ISSN: 0028-0836, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853129/pdf/nihms947051.pdf> DOI: 10.1038/nature25442 *
PHILIP MSCHIETINGER A: "CD8(+) T cell differentiation and dysfunction in cancer", NAT REV IMMUNOL, 2021
PISHESHA NINGRAM JRPLOEGH HLSORTASE A: "A Model for Transpeptidation and Its Biological Applications", ANNU REV CELL DEV BIOL., vol. 34, 2018, pages 163 - 88
PODRACKY, C.J. ET AL.: "Laboratory evolution of a sortase enzyme that modifies amyloid-beta protein", NAT CHEM BIOL, vol. 17, 2021, pages 317 - 325, XP037378486, DOI: 10.1038/s41589-020-00706-1
POPE M.E.SOSTE M.V.EYFORD B.A.ANDERSON N.L.PEARSON T.W., J. IMMUNOL. METHODS., vol. 341, no. 1-2, 2009, pages 86 - 96
QIN WU ET AL: "Hepta-Mutant Staphylococcus aureus Sortase A (SrtA 7m ) as a Tool for in Vivo Protein Labeling in Caenorhabditis elegans", ACS CHEMICAL BIOLOGY, vol. 12, no. 3, 18 January 2017 (2017-01-18), pages 664 - 673, XP055515863, ISSN: 1554-8929, DOI: 10.1021/acschembio.6b00998 *
RODGERS DTMAZAGOVA MHAMPTON ENCAO YRAMADOSS NSHARDY IR ET AL.: "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies", PROC NATL ACAD SCI U S A., vol. 113, no. 4, 2016, pages E459 - 68, XP055260066, DOI: 10.1073/pnas.1524155113
SHARMA PHU-LIESKOVAN SWARGO JARIBAS A: "Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy", CELL, vol. 168, no. 4, 2017, pages 707 - 23, XP029935389, DOI: 10.1016/j.cell.2017.01.017
YUN GE ET AL: "Enzyme-Mediated Intercellular Proximity Labeling for Detecting Cell?Cell Interactions", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 141, no. 5, 24 January 2019 (2019-01-24), pages 1833 - 1837, XP055726676, ISSN: 0002-7863, DOI: 10.1021/jacs.8b10286 *
ZONG YBICE TWTON-THAT HSCHNEEWIND ONARAYANA SV: "Crystal structures of Staphylococcus aureus sortase A and its substrate complex", J BIOL CHEM., vol. 279, no. 30, 2004, pages 31383 - 9

Also Published As

Publication number Publication date
WO2024027764A3 (fr) 2024-03-14
WO2024027764A2 (fr) 2024-02-08

Similar Documents

Publication Publication Date Title
JP6995151B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
US20190367621A1 (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
WO2019055946A1 (fr) Méthodes et compositions pour la modification génétique et l&#39;expansion de lymphocytes et la régulation de l&#39;activité de ces derniers
KR20200083986A (ko) Nyeso t 세포 수용체
CN107893052B (zh) 融合蛋白及其应用
KR20210150440A (ko) Mage a4 t 세포 수용체
US11325948B2 (en) Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US20220306723A1 (en) Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof
CA3152780A1 (fr) Methodes et compositions pour la modification et l&#39;administration de lymphocytes
US20210317408A1 (en) Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
WO2020047527A2 (fr) Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
CN113416260A (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
US20200299352A1 (en) Programmable immunocyte receptor complex system
JP2023515055A (ja) 阻害性キメラ受容体アーキテクチャ
WO2024026707A1 (fr) Systèmes de récepteurs antigéniques chimériques, procédés de préparation et utilisations de ceux-ci
WO2019028098A1 (fr) Procédés et compositions de traitement du cancer
WO2023241522A1 (fr) Récepteur de lymphocytes t ciblant un polypeptide mutant kras g12v, et son utilisation
US20220315894A1 (en) Method for Transduction of T Cells in the Presence of Malignant Cells
CN117264043B (zh) 靶向kras g12v突变多肽的t细胞受体及其用途
WO2018192443A1 (fr) Polypeptide et son application
KR20240005865A (ko) Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합
CN114702596A (zh) 靶向人cd33和nkg2dl的嵌合抗原受体细胞及其制备方法和应用
CN117750970A (zh) 包含nkg2d、cxcr2和dap10/dap12融合多肽的组合物及其使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22768614

Country of ref document: EP

Kind code of ref document: A1